Squalene synthase inhibition: A novel target for the management of dyslipidemia

Current Atherosclerosis Reports

Volumn 9, Issue 1, 2007, Pages 78-80

  Davidson, Michael H ^a  

^a RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BMS 188494; ER 27856; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; ROSUVASTATIN; RPR 107393; SIMVASTATIN; SQUALENE SYNTHASE; SQUALENE SYNTHASE INHIBITOR; SQUALESTATIN; T 91485; TAK 475; UNCLASSIFIED DRUG; YM 53601;

CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MYOPATHY; NONHUMAN; PATHOGENESIS; PLEIOTROPY; REVIEW; RISK MANAGEMENT; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS, PHASE III; DRUG DELIVERY SYSTEMS; DYSLIPIDEMIAS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; OXAZEPINES; PIPERIDINES;

EID: 33846146354     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02693932     Document Type: Review

References (22)

1. Grundy SM, Cleeman JI, Merz CN, et al.; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
2. Smith SC Jr, Allen J, Blair SN, et al.; AHA/ACC; National Heart, Lung, and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update; endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
3. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
4. Pedersen TR, Faergeman O, Kastelein JJ, et al.; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
5. Davidson MH, Maki KC, Pearson TA, et al.: Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005, 96:556-563.
6. Nissen SE, Nicholls SJ, Sipahi I, et al.: ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556-1565.
7. Robinson JG, Davidson MH: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006, 4:461-476.
8. Davidson MH, Robinson JG: Lipid-lowering effects of statins: a comparative review. Expert Opin Pharmacother 2006, 7:1701-1714.
9. Soma MR, Corsini A, Paoletti R: Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 1992, 64-65(Spec No):1-15.
10. Eggens I, Eriksson LC, Chojnacki T, Dallner G: Role of dolichyl phosphate in regulation of protein glycosylation in 2-acetylaminofluorene-induced carcinogenesis in rat liver. Cancer Res 1984, 44:799-805.
11. Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004, 109(23 Suppl 1):III39-43.
12. Hargreaves IP, Duncan AJ, Heales SJ, Land JM: The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications. Drug Safety 2005, 28:659-676.
13. Lamperti C, Naini AB, Lucchini V, et al.: Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005, 62:1709-1712.
14. Nakamura S: Total synthesis of the squalene synthase inhibitor zaragozic acid C. Chem Pharm Bull (Tokyo) 2005, 53:1-10.
15. Amin D, Rutledge RZ, Needle SN, et al.: RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 1997, 281:746-752.
16. Sharma A, Slugg PH, Hammett JL, Jusko WJ: Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol 1998, 38:1116-1121.
17. Hiyoshi H, Yanagimachi M, Ito M, et al.: Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J Lipid Res 2000, 41:1136-1144.
18. Ugawa T, Kakuta H, Moritani H, et al.: YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br J Pharmacol 2003, 139:140-146.
19. Miki T, Kori M, Mabuchi H, et al.: Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem 2002, 45:4571-4580.
20. Amano Y, Nishimoto T, Tozawa R, et al.: Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 2003, 466:155-161.
21. Nishimoto T, Tozawa R, Amano Y, et al.: Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003, 66:2133-2139.
22. Clinical Trials Database. Available at http://www.clinicaltrials.gov. Accessed September 5, 2006.